• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 5 - Emerging Agents

Article

It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination.

It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination. Dr George points out that all of the new therapies are based on an overall survival improvement, which is different from other cancer fields. He uses melanoma as an example where drugs are approved based upon a prolongation of survival of a small subset of patients. “Here, we are seeing improvements in the median survival of a broad unselected patient population of castration-resistant prostate cancer,” said Dr George.

Related Videos
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Rohan Garje, MD
Susan Escudier, MD, FACP
Sabarish Ayyappan, MD
Susan Escudier, MD, FACP
Screenshot of an interview with Evangelia Vlachou, MD
Screenshot of an interview with Barry Goy, MD
Debra Patt, MD, PhD, MBA, MPH
Clayton Irvine, PharmD, MBA, MS.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.